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Supplementary Table S2. Effect percentages for abnormal morphological characteristics evaluated in the zebrafish teratogenicity assay after exposure to coumarin derivate 7C. 
7C Embryotoxicitya Teratogenicitya Growth 
retardationb 




Yolk   
oedemab 








      
  
     
 
 100 μg/ml 20.0 80.0 0.0 37.5 62.5 87.5 0.0 0.0 0.0 100.0 
     
 
 10 μg/ml 20.0 80.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 
     
 
 1 μg/ml 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
     
 




      
  
     
 
 100 μg/ml 25.0 75.0 0.0 80.0 100.0 100.0 0.0 0.0 53.3 100.0 20.0 26.7 100.0 0.0 0.0  
 10 μg/ml 20.0 80.0 0.0 0.0 100.0 0.0 0.0 0.0 50.0 100.0 0.0 0.0 93.8 0.0 0.0  
 1 μg/ml 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  




      
  
     
 
 100 μg/ml 55.0 45.0 0.0 100.0 100.0 100.0 0.0 0.0 77.8 100.0 77.8 77.8 100.0 88.9 55.6 0.0 
 10 μg/ml 20.0 80.0 6.3 0.0 100.0 0.0 0.0 0.0 50.0 100.0 0.0 0.0 93.8 43.8 12.5 6.3 
 1 μg/ml 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 




      
  
     
 
 100 μg/ml 55.0 45.0 0.0 100.0 100.0 100.0 0.0 0.0 77.8 100.0 77.8 77.8 100.0 88.9 55.6  
 10 μg/ml 20.0 80.0 0.0 0.0 100.0 0.0 0.0 0.0 50.0 100.0 0.0 0.0 93.8 56.3 25.0  
 1 μg/ml 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
 
Supplementary Table S3. Effect percentages for abnormal morphological characteristics evaluated in the zebrafish teratogenicity assay after exposure to coumarin derivate 5,7C. 
5,7C Embryotoxicitya Teratogenicitya Growth 
retardationb 




Yolk   
oedemab 








      
  
     
 
 100 μg/ml 80.0 20.0 100.0 100.0 100.0 100.0 100.0 100.0 0.0 0.0            
 10 μg/ml 25.0 65.0 0.0 0.0 86.7 86.7 33.3 33.3 0.0 0.0 
     
 
 1 μg/ml 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
     
 




      
  
     
 
 100 μg/ml 100.0 0.0 - - - - - - - - - - - - -  
 10 μg/ml 55.0 45.0 0.0 0.0 100.0 77.8 0.0 0.0 77.8 77.8 0.0 0.0 100.0 0.0 100.0  
 1 μg/ml 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  




      
  
     
 
 100 μg/ml 100.0 0.0 - - - - - - - - - - - - - - 
 10 μg/ml 65.0 35.0 0.0 0.0 100.0 100.0 0.0 0.0 100.0 100.0 0.0 14.3 100.0 0.0 100.0 14.3 
 1 μg/ml 31.3 12.5 0.0 9.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 10.0 - 




      
  
     
 
 100 μg/ml 100.0 0.0 - - - - - - - - - - - - - - 
 10 μg/ml 85.0 15.0 0.0 0.0 100.0 100.0 0.0 0.0 100.0 100.0 66.7 66.7 100.0 0.0 100.0 33.3 
 1 μg/ml 37.5 6.3 10.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 - 
Abrevitation used: (hpf) hours post fertilisation; (-) data not available due to 100% mortality. 
a Percentage of mortality and teratogenicity based on all eggs. 
b Percentage of teratogenic effect based on all alive embryos at the time of assessment. 
 
 Supplementary Table S4. Effect percentages for abnormal morphological characteristics evaluated in the zebrafish teratogenicity assay after exposure to coumarin derivate 7,8C. 
7,8C Embryotoxicitya Teratogenicitya Growth 
retardationb 




Yolk   
oedemab 








      
  
     
 
 100 μg/ml 100.00 0.0 - - - - - - -   -   
 
       
 10 μg/ml 90.00 10.0 100.0 100.0 0.0 100.0 100.0 100.0 0.0 0.0 
     
 
 1 μg/ml 30.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
  
       




      
  
     
 
 100 μg/ml 100.00 0.0 - - - - - - - - - - - - -  
 10 μg/ml 100.00 0.0 - - - - - - - - - - - - -  
 1 μg/ml 30.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  




      
  
     
 
 100 μg/ml 100.00 0.0 - - - - - - - - - - - - - - 
 10 μg/ml 100.00 0.0 - - - - - - - - - - - - - - 
 1 μg/ml 30.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 




      
  
     
 
 100 μg/ml 100.00 0.0 - - - - - - - - - - - - - - 
 10 μg/ml 100.00 0.0 - - - - - - - - - - - - - - 
 1 μg/ml 30.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 
Supplementary Table S5. Effect percentages for abnormal morphological characteristics evaluated in the zebrafish teratogenicity assay after exposure to coumarin. 
Coumarin Embryotoxicitya Teratogenicitya Growth 
retardationb 




Yolk   
oedemab 








      
  
     
 
 100 μg/ml 55.0 30.0 33.3 0.0 33.3 33.3 33.3 44.4 0.0 0.0 
     
 
 10 μg/ml 43.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
     
 
 1 μg/ml 25.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
     
 




      
  
     
 
 100 μg/ml 60.0 40.0 12.5 87.5 0.0 100.0 0.0 0.0 100.0 100.0 25.0 37.5 100.0 0.0 12.5  
 10 μg/ml 43.8 0.0 0.0 0.0 0.0 0.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
 1 μg/ml 25.0 0.0 0.0 0.0 0.0 0.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  




      
  
     
 
 100 μg/ml 60.0 40.0 50.0 87.5 0.0 100.0 0.0 0.0 100.0 100.0 37.5 50.0 100.0 25.0 50.0 50.0 
 10 μg/ml 43.8 37.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 66.7 0.0 
 1 μg/ml 35.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.7 0.0 7.7 0.0 0.0 




      
  
     
 
 100 μg/ml 85.0 15.0 0.0 100.0 0.0 100.0 0.0 0.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 0.0 
 10 μg/ml 43.8 37.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 66.7 0.0 
 1 μg/ml 55.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Abrevitation used: (hpf) hours post fertilisation; (-) data not available due to 100% mortality. 
a Percentage of mortality and teratogenicity based on all eggs. 
b Percentage of teratogenic effect based on all alive embryos at the time of assessment. 
